We read with interest the recent reviews published in Gut , emphasising that even though the understanding of the pathobiology of liver fibrosis has been improved in the last three decades,1 novel and easy to implement diagnostic and therapeutic approaches are required.2 Indeed, fibrosis is the most important histological feature of patients with chronic liver disease (CLD), such as non-alcoholic fatty liver disease, and is associated with long-term overall mortality, liver transplantation and liver-related events.3 Diagnostic and therapeutic approaches,2 therefore, require accurate measurements that ideally allow non-invasive fibrosis quantification, representing the whole liver free of bias and easily integrated in clinical routine. A liver biopsy, still the reference standard, has substantial drawbacks (complications, intraobserver and interobserver variabilities).4 Transient elastography (TE), suggested for population-wide screens (eg, patients with diabetes),5 requires additional expensive devices and trained personnel. However, contrast-enhanced MRI is routinely performed and recommended in patients with CLD for exclusion of hepatocellular …

中文翻译：

---

包括细胞外体积分数在内的定量肝脏 MRI，用于无创量化肝纤维化：一项前瞻性概念验证研究

我们饶有兴趣地阅读了最近发表在 Gut 上的评论，强调尽管在过去的三十年里对肝纤维化病理生物学的理解有所提高 1，但仍需要新颖且易于实施的诊断和治疗方法。 2 事实上，纤维化是慢性肝病 (CLD) 患者最重要的组织学特征，如非酒精性脂肪肝，与长期总体死亡率、肝移植和肝脏相关事件相关。 3 诊断和治疗方法，2 因此，需要准确的测量，理想情况下允许非侵入性纤维化量化，代表整个肝脏没有偏见并易于整合到临床常规中。肝活检仍然是参考标准，但存在很大的缺陷（并发症、观察者内和观察者间的变异性。4 瞬态弹性成像 (TE)，建议用于全人群筛查（例如，糖尿病患者）5 需要额外的昂贵设备和训练有素的人员。然而，对于 CLD 患者，常规进行对比增强 MRI 以排除肝细胞…